{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"14"},{"groupId":"OG001","value":"30"},{"groupId":"OG002","value":"26"},{"groupId":"OG003","value":"21"},{"groupId":"OG004","value":"20"},{"groupId":"OG005","value":"14"}]}],"title":"TEAE"},{"categories":[{"measurements":[{"groupId":"OG000","value":"14"},{"groupId":"OG001","value":"30"},{"groupId":"OG002","value":"25"},{"groupId":"OG003","value":"21"},{"groupId":"OG004","value":"20"},{"groupId":"OG005","value":"13"}]}],"title":"Grade 3-5 TEAE"},{"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"1"},{"groupId":"OG002","value":"1"},{"groupId":"OG003","value":"2"},{"groupId":"OG004","value":"0"},{"groupId":"OG005","value":"0"}]}],"title":"Grade 5 TEAE"},{"categories":[{"measurements":[{"groupId":"OG000","value":"12"},{"groupId":"OG001","value":"26"},{"groupId":"OG002","value":"25"},{"groupId":"OG003","value":"21"},{"groupId":"OG004","value":"20"},{"groupId":"OG005","value":"14"}]}],"title":"JCARH125-Related TEAE"},{"categories":[{"measurements":[{"groupId":"OG000","value":"5"},{"groupId":"OG001","value":"10"},{"groupId":"OG002","value":"15"},{"groupId":"OG003","value":"16"},{"groupId":"OG004","value":"16"},{"groupId":"OG005","value":"7"}]}],"title":"JCARH125-Related Grade 3-5 TEAE"},{"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"1"},{"groupId":"OG004","value":"0"},{"groupId":"OG005","value":"0"}]}],"title":"JCARH125-Related Grade 5 TEAE"}],"denoms":[{"counts":[{"groupId":"OG000","value":"14"},{"groupId":"OG001","value":"30"},{"groupId":"OG002","value":"26"},{"groupId":"OG003","value":"21"},{"groupId":"OG004","value":"20"},{"groupId":"OG005","value":"14"}],"units":"Participants"}],"description":"TEAE is defined as an AE that starts any time from initiation of JCARH125 administration through and including 90 days following the JCARH125 infusion graded using the NCI Common Terminology Criteria for Adverse Events (CTCAE), version 4.03. Any AE occurring after the initiation of another anticancer treatment will not be considered a TEAE. Grade 3=Severe; Grade 4=Life-threatening; and Grade 5=death.","groups":[{"description":"JCARH125 IV at dose level 50 x 10\\^6 consisting of CD3+CAR+T cells","id":"OG000","title":"Phase 1 50 x 10^6 Cells"},{"description":"JCARH125 IV at dose level 150 x 10\\^6 consisting of CD3+CAR+T cells","id":"OG001","title":"Phase 1 150 x 10^6 Cells"},{"description":"JCARH125 IV at dose level 300 x 10\\^6 consisting of CD3+CAR+T cells","id":"OG002","title":"Phase 1 300 x 10^6 Cells"},{"description":"JCARH125 IV at dose level 450 x 10\\^6 consisting of CD3+CAR+T cells","id":"OG003","title":"Phase 1 450 x 10^6 Cells"},{"description":"JCARH125 IV at dose level 600 x 10\\^6 consisting of CD3+CAR+T cells","id":"OG004","title":"Phase 1 600 x 10^6 Cells"},{"description":"2 doses of 100 mg anakinra administered subcutaneously (SC) for 5 consecutive days + JCARH125 IV at dose level 600 x 10\\^6 consisting of CD3+CAR+T cells","id":"OG005","title":"Phase 1 Anakinra 600 x 10^6 Cells"}],"paramType":"COUNT_OF_PARTICIPANTS","populationDescription":"All participants who received at least one infusion of JCARH125 (and at least one dose of anakinra as prophylactic intervention for phase 1 Anakinra) in phase 1 and in phase 1 Anakinra","reportingStatus":"POSTED","timeFrame":"From the time of JCARH125 infusion to 90 days following the infusion (Up to 90 days)","title":"Number of Participants With Treatment-Emergent Adverse Events (TEAEs) by Severity in Phase 1 and Phase 1 Anakinra","type":"PRIMARY","unitOfMeasure":"Participants"}